Infectious Disease

AstraZeneca completes Icosavax acquisition for $1.1bn

AstraZeneca has concluded the acquisition of the US-based clinical-stage biopharmaceutical company Icosavax in a $1.1bn deal. The latest development comes…

FDA grants fast track status to GSK’s bepirovirsen for hepatitis B

The US Food and Drug Administration (FDA) has granted fast track designation to GSK’s bepirovirsen, an investigational treatment for chronic…

Emergent wins $235.8m US defence contract for Anthrax vaccine

The US Department of Defense (DoD) has awarded a procurement contract worth up to $235.8m to Emergent BioSolutions for an…

Curevo looks to challenge GSK’s Shingrix with positive Phase II data

Curevo Vaccine’s varicella-zoster virus vaccine amezosvatein has achieved all primary endpoints, including demonstrating non-inferiority to GSK’s Shingrix in a Phase…

FDA accepts Merck’s pneumococcal vaccine BLA for priority review

The US Food and Drug Administration (FDA) has accepted the new biologics licence application (BLA) for MSD’s investigational 21-valent pneumococcal…

Health Canada authorises Novavax’s updated Covid-19 vaccine 

Health Canada has granted expanded authorisation for Novavax’s updated Covid-19 vaccine, Nuvaxovid XBB.1.5 (recombinant protein, adjuvanted) [NVX-CoV2601]. The vaccine is…

Biocon integrates Viatris biosimilars in 31 European countries

Biocon subsidiary Biocon Biologics has successfully integrated Viatris' biosimilars business in 31 countries in Europe. In November 2022, Biocon Biologics…

Japan grants approval for CSL and Arcturus’ Covid-19 vaccine 

Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved CSL and Arcturus Therapeutics’ self-amplifying mRNA (sa-mRNA) Covid-19 vaccine, ARCT-154.  The…

Emergent wins $75m BARDA contact for anthrax vaccine

Emergent BioSolutions has secured a $75m contract for the acquisition of the FDA-approved anthrax vaccine, Cyfendus. The contract was awarded…

Boehringer to leverage IBM’s technologies for antibody discovery 

Boehringer Ingelheim has entered an agreement with IBM to leverage the latter’s foundation model technologies for novel antibody discovery and…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close